Description: Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug with safety profile for the prevention and treatment of dengue fever and other mosquito borne diseases. The company was founded in 2017 and is based in Camberwell, Australia.
Home Page: www.islandpharmaceuticals.com
ILA Technical Analysis
AIM Growth Series
,
Phone:
800-959-4246
Officers
| Name | Title |
|---|---|
| Dr. Paul Donald Richard MacLeman M.B.A., MBA, BVSc, Grad Dip Tech, Grad Cert Eng, G | Exec. Chairman |
| Dr. David Charles Foster | MD, CEO, Pres & Exec. Director |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2935 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |